Okuyama Kishima Marina, de Oliveira Carlos Eduardo Coral, Banin-Hirata Bruna Karina, Losi-Guembarovski Roberta, Brajão de Oliveira Karen, Amarante Marla Karine, Watanabe Maria Angelica Ehara
Laboratory of Human Pathology, Department of Pathology, Clinical Analysis and Toxicology, Health Sciences Center, University Hospital of Londrina, State University of Londrina, 86038-350 Londrina, PR, Brazil.
Laboratory of Study and Application of DNA Polymorphisms and Immunology, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina, 86057-970 Londrina, PR, Brazil.
Anal Cell Pathol (Amst). 2015;2015:891020. doi: 10.1155/2015/891020. Epub 2015 Jun 16.
Many tumor cells express chemokines and chemokine receptors, and, for this reason, these molecules can affect the tumor progression. It is known that breast cancer is a complex and heterogeneous neoplasia comprising distinct diseases, histological characteristics, and clinical outcomes. The most studied role for CXCL12 chemokine and its receptor CXCR4 in breast cancer pathogenesis is the metastasis event, although several reports have demonstrated its involvement in other processes, such as angiogenesis and tumor growth. It has been found that CXCR4 is required for breast cancer cell migration to other sites such as lung, bone, and lymph nodes, which express high levels of CXCL12 chemokine. Therefore, CXCR4 is being considered a prognostic marker in breast cancer. Within this context, this review summarizes established studies involving expression of CXCR4 on breast cancer, focusing on its clinical significance.
许多肿瘤细胞表达趋化因子和趋化因子受体,因此,这些分子会影响肿瘤进展。众所周知,乳腺癌是一种复杂的异质性肿瘤,包含不同的疾病、组织学特征和临床结果。虽然有几份报告表明CXCL12趋化因子及其受体CXCR4参与了诸如血管生成和肿瘤生长等其他过程,但在乳腺癌发病机制中,对其研究最多的作用是转移事件。已发现乳腺癌细胞迁移至肺、骨和淋巴结等表达高水平CXCL12趋化因子的其他部位需要CXCR4。因此,CXCR4被视为乳腺癌的一种预后标志物。在此背景下,本综述总结了有关CXCR4在乳腺癌中表达的既定研究,重点关注其临床意义。